SEC Comment Letter 0000000000-24-009079 to LEXICON PHARMACEUTICALS, INC. (LXRX) (CIK 0001062822) (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX) (CIK 0001062822)
Date: Aug. 8, 2024 · CIK: 0001062822 · Accession: 0000000000-24-009079
AI Filing Summary & Sentiment
File numbers found in text: 333-281208
Letter
August 8, 2024 Michael Exton Chief Executive Officer Lexicon Pharmaceuticals, Inc. 2445 Technology Forest Blvd., 11th Floor The Woodlands, TX 77381 Re:Lexicon Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 2, 2024 File No. 333-281208 Dear Michael Exton: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jackson O'Maley
Show Raw Text
August 8, 2024
Michael Exton
Chief Executive Officer
Lexicon Pharmaceuticals, Inc.
2445 Technology Forest Blvd., 11th Floor
The Woodlands, TX 77381
Re:Lexicon Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 2, 2024
File No. 333-281208
Dear Michael Exton:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jackson O'Maley